Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 351 of 5804
-
New cocktail targets Stomach-Lining pancreatic cancer
Disease control Recruiting nowThis goal of this clinical trial is to learn whether the drug combination of intraperitoneal paclitaxel (chemotherapy given directly into the abdominal cavity) and intravenous NALIRIFOX (chemotherapy given into a vein, including fluorouracil, leucovorin, oxaliplatin, and liposoma…
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New breast cancer cocktail aims to ditch chemo before surgery
Disease control Not yet recruitingTo further enhance treatment efficacy, minimize reliance on chemotherapy, and identify the optimal neoadjuvant approach for ER-positive and HER2-positive population, we have designed a single-arm, phase II clinical trial. This study aims to evaluate the efficacy and safety of a n…
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo therapy targets liver tumors from eye cancer
Disease control Recruiting nowThis Phase 2 study evaluates the efficacy and safety of sequential treatment with percutaneous hepatic perfusion (PHP) using melphalan/HDS followed by tebentafusp in patients with metastatic uveal melanoma (mUM) with isolated liver metastases. The rationale is that PHP enhances a…
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New cell therapy offers hope for Hard-to-Treat lymphoma patients
Disease control Not yet recruitingEvaluate the safety and tolerability of AcNK-Sup003 cell injection in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). To preliminarily determine the Maximum Tolerated Dose (MTD) or recommended clinical dose of AcNK-Sup003 cell injection.
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Blood test may predict liver cancer comeback and immunotherapy success
Knowledge-focused Not yet recruitingHepatocellular carcinoma (HCC) is a leading global cause of cancer-related mortality. While curative resection is pivotal, high postoperative recurrence rates remain a major challenge. Adjuvant immune checkpoint inhibitors (ICIs) show promise in improving outcomes, but biomarkers…
Phase: NA • Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
New four-drug cocktail targets tough liver cancers with promising early trial
Disease control Not yet recruitingIn China, the majority of hepatocellular carcinoma (HCC) cases stem from chronic hepatitis B virus (HBV) infection and subsequent cirrhosis, with patients often presenting at the decompensated stage complicated by clinically significant portal hypertension (CSPH). CSPH not only l…
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Could stem cells help stroke patients recover? new trial launches
Disease control Recruiting nowThis Phase I/IIa, randomized, double-blind, placebo-controlled study evaluates the safety, tolerability, and preliminary efficacy of B2065, an allogeneic adipose-derived mesenchymal stromal cell (AD-MSC) injection, in patients with acute ischemic stroke. Participants receive a si…
Phase: PHASE1, PHASE2 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for advanced bowel cancer: experimental drug combo enters major trial
Disease control Recruiting nowThe purpose of this study is to evaluate the safety and efficacy of pumitamig in combination with chemotherapy versus bevacizumab in combination with chemotherapy in participants with previously untreated, unresectable, or metastatic colorectal cancer
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Stem cell showdown: donor or self? new trial aims to improve lymphoma outcomes
Disease control Recruiting nowThis study is a multicenter, two-arm, prospective clinical trial, comprising two groups: the allogeneic hematopoietic stem cell transplantation group (Allo-HSCT) and the autologous hematopoietic stem cell transplantation group (Auto-HSCT). It aims to evaluate the efficacy and saf…
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Triple-threat treatment aims to make inoperable lung cancer removable
Disease control Recruiting nowThis is a Phase II clinical trial evaluating the efficacy and safety of a new treatment approach for patients with locally advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes on the opposite side of the chest (known as N3 lymph node involvement). The study…
Phase: PHASE2 • Sponsor: Yang Hong • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo therapy offers hope for hard-to-treat lymphoma patients
Disease control Not yet recruitingFor relapsed/refractory mantle cell lymphoma patients that previously treated with BTK inhibitors: The first part involves 6 cycles of combined therapy with zuberitamab, selinexor, dexamethasone, and thalidomide. This targeted combination regimen can enhance efficacy while reduci…
Phase: PHASE4 • Sponsor: Zhengzhou University • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Could a common antibiotic help brain bleed patients?
Disease control Not yet recruitingThis study plans to enroll 1248 patients with supratentorial ICH within 24 hours of onset across multiple stroke centers. After randomization, the control group will only receive medical therapy. The experimental group, after randomization, will receive an initial dose of 200 mg …
Phase: NA • Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug combo aims to fight colorectal cancer when standard chemo fails
Disease control Not yet recruitingFruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with chemotherapy. Trifluridine/tipiracil plus bevacizumab is also a standard treatment for mCRC…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
One-Shot gene therapy could free PKU patients from strict diet
Disease control Not yet recruitingThis study is a single-arm, open-label, dose-escalation, exploratory study to evaluate the safety, tolerability, and efficacy of a single administration of GS1168 Injection in Chinese adult phenylketonuria (PKU) with PAH mutation.
Phase: EARLY_PHASE1 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo aims to shrink liver tumors before surgery
Disease control Recruiting nowThis study is a prospective, single-arm, phase Ⅱtrial. The subjects are patients resectable centrally-located hepatocellular carcinoma in BCLC stage B who are admitted to the Hepatobiliary Surgery Department of Tongji Hospital , Tongji Medical College, Huazhong University of Scie…
Phase: PHASE2 • Sponsor: Wei Zhang • Aim: Disease control
Last updated Jun 26, 2026 14:09 UTC
-
New drug combo shows promise for tough cervical cancers
Disease control Not yet recruitingThis trial is a national multicenter, open-label, non-interventional study to observe and evaluate the safety and efficacy of monotherapy or combination regimens based on camrelizumab or famitinib in patients with cervical cancer. This study included patients with cervical cance…
Sponsor: Qi Zhou • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New dissolving heart plug could stop strokes without lifelong drugs
Disease control Not yet recruitingTo evaluate the Safety and Efficacy of a Novel Biodegradable Occluder for Percutaneous Closure of Patent Foramen Ovale (PFO)
Phase: NA • Sponsor: Shanghai Lingsi Medical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo aims to shrink Hard-to-Operate ovarian tumors
Disease control Not yet recruitingThis study is a randomized, open-label, double-cohort, national multi-center clinical research. The aim is to evaluate the newly diagnosed FIGO 2014 stage III-IV pathology of neoadjuvant therapy with fluzoparib combined with famitinib or fluzoparib combined with SHR-1701, based o…
Phase: PHASE2 • Sponsor: Qinglei Gao • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New sensor could spot hidden heart attacks in minutes
Diagnosis TerminatedThe objective of this prospective, cross-sectional, multicenter pivotal trial study is to validate Infrasensor's clinical performance for the detection of high grade obstructive NSTE-ACS. High-grade obstructive NSTE-ACS is defined as an acute coronary syndrome in which severe obs…
Sponsor: Remote Cardiac Enablement • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Electric fields plus targeted radiation may boost survival in recurrent glioblastoma
Disease control Recruiting nowThis study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma. Patients with recurrent glioblastoma have limited treatment options an…
Phase: NA • Sponsor: Prof. Franciszek Lukaszczyk Memorial Oncology Center • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC